Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells

Cancer Cell

Volumn 3, Issue 3, 2003, Pages 285-296

  Dolma, Sonam ^a   Lessnick, Stephen L ^b,c   Hahn, William C ^b,d   Stockwell, Brent R ^a  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BOUVARDIN; CAMPTOTHECIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ECHINOMYCIN; ERASTIN; MITOXANTRONE; NSC 146109; ONCOPROTEIN; RAS PROTEIN; SANGIVAMYCIN; TELOMERASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; CALCEIN AM; DIAGNOSTIC AGENT; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; PIPERAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; GENE OVEREXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE; PAPILLOMA VIRUS; PRIORITY JOURNAL; SENSITIZATION; SIMIAN VIRUS 40; TUMOR CELL; CELL CULTURE; CELL DEATH; CELL LINE; CHEMICAL STRUCTURE; DRUG SCREENING; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETICS; IC 50; METABOLISM; RETROVIRUS; VIRUS CELL TRANSFORMATION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; SIMIAE; SIMIAN VIRUS 40;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE; CELL TRANSFORMATION, VIRAL; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; FLUORESCEINS; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ENGINEERING; GENOTYPE; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; ONCOGENE PROTEINS; PIPERAZINES; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0037932865     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00050-3     Document Type: Article

References (59)

1. Ahmed S.A., Gogal R.M., Walsh J.E. A new rapid and non-radioactive assay to monitor and determine the proliferation of lymphocytes. an alternative to [3H]-thymidine incorporation assay J. Immunol. Methods. 170:1994;211-224.
2. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA. 84:1987;5565-5569.
3. Bjornsti M.A., Benedetti P., Viglianti G.A., Wang J.C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I. restoration of sensitivity of the cells to the antitumor drug camptothecin Cancer Res. 49:1989;6318-6323.
4. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:2002;244-265.
5. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:1994;756-758.
6. Calin G.A., di Iasio M.G., Caprini E., Vorechovsky I., Natali P.G., Sozzi G., Croce C.M., Barbanti-Brodano G., Russo G., Negrini M. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene. 19:2000;1191-1195.
7. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:2002;493-502.
8. Champoux J.J. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Ann. N Y Acad. Sci. 922:2000;56-64.
9. Chan Y.M., Wu W., Yip H.K., So K.F., Oppenheim R.W. Caspase inhibitors promote the survival of avulsed spinal motoneurons in neonatal rats. Neuroreport. 12:2001;541-545.
10. D'Arpa P., Beardmore C., Liu L.F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50:1990;6919-6924.
11. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
12. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., Popescu N.C., Hahn W.C., Weinberg R.A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15:2001;50-65.
13. Eng W.K., Faucette L., Johnson R.K., Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34:1988;755-760.
14. Hahn W.C., Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer. 2:2002;331-341.
15. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
16. Hahn W.C., Dessain S.K., Brooks M.W., King J.E., Elenbaas B., Sabatini D.M., DeCaprio J.A., Weinberg R.A. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 22:2002;2111-2123.
17. Hamad N.M., Elconin J.H., Karnoub A.E., Bai W., Rich J.N., Abraham R.T., Der C.J., Counter C.M. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16:2002;2045-2057.
18. Harley C.B. Telomerases. Pathol. Biol. (Paris). 42:1994;342-345.
19. Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726.
20. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
21. Jorcyk C.L., Liu M.L., Shibata M.A., Maroulakou I.G., Komschlies K.L., McPhaul M.J., Resau J.H., Green J.E. Development and characterization of a mouse prostate adenocarcinoma cell line. ductal formation determined by extracellular matrix Prostate. 34:1998;10-22.
22. Kohno T., Takakura S., Yamada T., Okamoto A., Tanaka T., Yokota J. Alterations of the PPP1R3 gene in human cancer. Cancer Res. 59:1999;4170-4174.
23. Laurent G., Jaffrezou J.P. Signaling pathways activated by daunorubicin. Blood. 98:2001;913-924.
24. Lessnick S.L., Dacwag C.S., Golub T.R. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell. 1:2002;393-401.
25. Liu L.F., Desai S.D., Li T.K., Mao Y., Sun M., Sim S.P. Mechanism of action of camptothecin. Ann. N Y Acad. Sci. 922:2000;1-10.
26. Loomis C.R., Bell R.M. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J. Biol. Chem. 263:1988;1682-1692.
27. Madden K.R., Champoux J.J. Overexpression of human topoisomerase I in baby hamster kidney cells. hypersensitivity of clonal isolates to camptothecin Cancer Res. 52:1992;525-532.
28. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146:1995;3-15.
29. Makin G. Targeting apoptosis in cancer chemotherapy. Expert Opin. Ther. Targets. 6:2002;73-84.
30. Millward T.A., Zolnierowicz S., Hemmings B.A. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem. Sci. 24:1999;186-191.
31. Mokbel K., Hassanally D. From HER2 to herceptin. Curr. Med. Res. Opin. 17:2001;51-59.
32. Muller I., Niethammer D., Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int. J. Mol. Med. 1:1998;491-494.
33. Nociari M.M., Shalev A., Benias P., Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J. Immunol. Methods. 13:1998;157-167.
34. Perez-Stable C., Altman N.H., Mehta P.P., Deftos L.J., Roos B.A. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res. 57:1997;900-906.
35. Rao K.V. Structure of sangivamycin. J. Med. Chem. 11:1968;939-941.
36. Rich J.N., Guo C., McLendon R.E., Bigner D.D., Wang X.F., Counter C.M. A genetically tractable model of human glioma formation. Cancer Res. 61:2001;3556-3560.
37. Richard D., Morjani H., Chenais B. Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines. Leuk. Res. 26:2002;927-931.
38. Ruediger R., Pham H.T., Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene. 20:2001;1892-1899. a.
39. Ruediger R., Pham H.T., Walter G. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene. 20:2001;10-15. b.
40. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1. a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast tors Cell. 78:1994;35-43.
41. Sandmoller A., Halter R., Suske G., Paul D., Beato M. A transgenic mouse model for lung adenocarcinoma. Cell Growth Differ. 6:1995;97-103.
42. Schreiber S.L. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem. 6:1998;1127-1152.
43. Sellers W.R., Kaelin W.G. Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol. 15:1997;3301-3312.
44. Shawver L.K., Slamon D., Ullrich A. Smart drugs. tyrosine kinase inhibitors in cancer therapy Cancer Cell. 1:2002;117-123.
45. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2:2001;731-737.
46. Shi Y., Gera J., Hu L., Hsu J.H., Bookstein R., Li W., Lichtenstein A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62:2002;5027-5034.
47. Simons A., Dafni N., Dotan I., Oron Y., Canaani D. Establishment of a chemical synthetic lethality screen in cultured human cells. Genome Res. 11:2001;266-273.
48. Stockwell B.R. Chemical genetics. ligand-based discovery of gene function Nat. Rev. Genet. 1:2000;116-125. a.
49. Stockwell B.R. Frontiers in chemical genetics. Trends Biotechnol. 18:2000;449-455. b.
50. Stockwell B.R., Haggarty S.J., Schreiber S.L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 6:1999;71-83.
51. Testa J.R., Giordano A. SV40 and cell cycle perturbations in malignant mesothelioma. Semin. Cancer Biol. 11:2001;31-38.
52. Torrance C.J., Agrawal V., Vogelstein B., Kinzler K.W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19:2001;940-945.
53. Traganos F., Seiter K., Feldman E., Halicka H.D., Darzynkiewicz Z. Induction of apoptosis by camptothecin and topotecan. Ann. N Y Acad. Sci. 803:1996;101-110.
54. Tsao Y.P., Russo A., Nyamuswa G., Silber R., Liu L.F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes. studies in a cell-free SV40 DNA replication system Cancer Res. 53:1993;5908-5914.
55. Van Dyke M.M., Dervan P.B. Echinomycin binding sites on DNA. Science. 225:1984;1122-1127.
56. Wang X.M., Terasaki P.I., Rankin G.W.J., Chia D., Zhong H.P., Hardy S. A new microcellular cytotoxicity test based on calcein AM release. Hum. Immunol. 37:1993;264-270.
57. Wang S.S., Esplin E.D., Li J.L., Huang L., Gazdar A., Minna J., Evans G.A. Alterations of the PPP2R1B gene in human lung and colon cancer. Science. 282:1998;284-287.
58. Waring M.J., Wakelin L.P. Echinomycin. a bifunctional intercalating antibiotic Nature. 252:1974;653-657.
59. Zalacain M., Zaera E., Vazquez D., Jimenez A. The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells. FEBS Lett. 148:1982;95-97.